Cargando…

Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA

Osteoarthritis (OA) is closely linked to the increase in the number of senescent cells in joint tissues, and the senescence-associated secretory phenotype (SASP) is implicated in cartilage degradation. In the last decade, extracellular vesicles (EV) in combination with the use of miRNAs to modify po...

Descripción completa

Detalles Bibliográficos
Autores principales: Morente-López, Miriam, Mato-Basalo, Rocío, Lucio-Gallego, Sergio, Silva-Fernández, Lucía, González-Rodríguez, Alba, De Toro, Fco. Javier, Fafián-Labora, Juan A., Arufe, María C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584990/
https://www.ncbi.nlm.nih.gov/pubmed/36264388
http://dx.doi.org/10.1007/s00018-022-04580-z
_version_ 1784813398330966016
author Morente-López, Miriam
Mato-Basalo, Rocío
Lucio-Gallego, Sergio
Silva-Fernández, Lucía
González-Rodríguez, Alba
De Toro, Fco. Javier
Fafián-Labora, Juan A.
Arufe, María C.
author_facet Morente-López, Miriam
Mato-Basalo, Rocío
Lucio-Gallego, Sergio
Silva-Fernández, Lucía
González-Rodríguez, Alba
De Toro, Fco. Javier
Fafián-Labora, Juan A.
Arufe, María C.
author_sort Morente-López, Miriam
collection PubMed
description Osteoarthritis (OA) is closely linked to the increase in the number of senescent cells in joint tissues, and the senescence-associated secretory phenotype (SASP) is implicated in cartilage degradation. In the last decade, extracellular vesicles (EV) in combination with the use of miRNAs to modify post-transcriptional expressions of multiple genes have shown their utility in new therapies to treat inflammatory diseases. This work delves into the anti-inflammatory effect of extracellular vesicles derived from mesenchymal stem cells (MSC) previously modified to inhibit the expression of miR-21. We compare the efficacy of two treatments, MSC with their miR-21 inhibited through lentiviral transfection and their EV, against inflammation in a new OA animal model. The modified MSC and their EV were intraperitoneally injected in an OA animal model twice. One month after treatment, we checked which therapy was the most effective to reduce inflammation compared with animals untreated. Treated OA model sera were analyzed for cytokines and chemokines. Subsequently, different organs were analyzed to validate the results obtained. EV were the most effective treatment to reduce chemokines and cytokines in serum of OA animals as well as SASP, in their organs checked by proteomic and genomic techniques, compared with MSC alone in a statistically significant way. In conclusion, MSC-miR-21(−)-derived EV showed a higher therapeutic potential in comparison with MSCs-miR-21-. They ameliorate the systemic inflammation through inactivation of ERK1/2 pathway in OA in vivo model. GRAPHICAL ABSTRACT: Workflow of the realization of the animal model of OA by injecting cells into the joint cavity of the left knee of the animals, which produces an increase in serum cytokines and chemokines in the animals in addition to the increase in SASP and markers of inflammation. Inhibition of miR-21 in MSCs, from the stroma of the human umbilical cord, by lentivirus and extraction of their EVs by ultracentrifugation. Finally, application of MSC therapy with its miR-21 inhibited or its EVs produces a decrease in serum cytokines and chemokines in the treated animals, in addition to an increase in SASP and markers of inflammation. The cell-free therapy being the one that produces a greater decrease in the parameters studied [Image: see text]
format Online
Article
Text
id pubmed-9584990
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-95849902022-10-22 Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA Morente-López, Miriam Mato-Basalo, Rocío Lucio-Gallego, Sergio Silva-Fernández, Lucía González-Rodríguez, Alba De Toro, Fco. Javier Fafián-Labora, Juan A. Arufe, María C. Cell Mol Life Sci Original Article Osteoarthritis (OA) is closely linked to the increase in the number of senescent cells in joint tissues, and the senescence-associated secretory phenotype (SASP) is implicated in cartilage degradation. In the last decade, extracellular vesicles (EV) in combination with the use of miRNAs to modify post-transcriptional expressions of multiple genes have shown their utility in new therapies to treat inflammatory diseases. This work delves into the anti-inflammatory effect of extracellular vesicles derived from mesenchymal stem cells (MSC) previously modified to inhibit the expression of miR-21. We compare the efficacy of two treatments, MSC with their miR-21 inhibited through lentiviral transfection and their EV, against inflammation in a new OA animal model. The modified MSC and their EV were intraperitoneally injected in an OA animal model twice. One month after treatment, we checked which therapy was the most effective to reduce inflammation compared with animals untreated. Treated OA model sera were analyzed for cytokines and chemokines. Subsequently, different organs were analyzed to validate the results obtained. EV were the most effective treatment to reduce chemokines and cytokines in serum of OA animals as well as SASP, in their organs checked by proteomic and genomic techniques, compared with MSC alone in a statistically significant way. In conclusion, MSC-miR-21(−)-derived EV showed a higher therapeutic potential in comparison with MSCs-miR-21-. They ameliorate the systemic inflammation through inactivation of ERK1/2 pathway in OA in vivo model. GRAPHICAL ABSTRACT: Workflow of the realization of the animal model of OA by injecting cells into the joint cavity of the left knee of the animals, which produces an increase in serum cytokines and chemokines in the animals in addition to the increase in SASP and markers of inflammation. Inhibition of miR-21 in MSCs, from the stroma of the human umbilical cord, by lentivirus and extraction of their EVs by ultracentrifugation. Finally, application of MSC therapy with its miR-21 inhibited or its EVs produces a decrease in serum cytokines and chemokines in the treated animals, in addition to an increase in SASP and markers of inflammation. The cell-free therapy being the one that produces a greater decrease in the parameters studied [Image: see text] Springer International Publishing 2022-10-20 2022 /pmc/articles/PMC9584990/ /pubmed/36264388 http://dx.doi.org/10.1007/s00018-022-04580-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Morente-López, Miriam
Mato-Basalo, Rocío
Lucio-Gallego, Sergio
Silva-Fernández, Lucía
González-Rodríguez, Alba
De Toro, Fco. Javier
Fafián-Labora, Juan A.
Arufe, María C.
Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA
title Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA
title_full Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA
title_fullStr Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA
title_full_unstemmed Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA
title_short Therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in OA
title_sort therapy free of cells vs human mesenchymal stem cells from umbilical cord stroma to treat the inflammation in oa
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584990/
https://www.ncbi.nlm.nih.gov/pubmed/36264388
http://dx.doi.org/10.1007/s00018-022-04580-z
work_keys_str_mv AT morentelopezmiriam therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa
AT matobasalorocio therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa
AT luciogallegosergio therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa
AT silvafernandezlucia therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa
AT gonzalezrodriguezalba therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa
AT detorofcojavier therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa
AT fafianlaborajuana therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa
AT arufemariac therapyfreeofcellsvshumanmesenchymalstemcellsfromumbilicalcordstromatotreattheinflammationinoa